Vitamin D and Cancer

Presentation by Rondo P. Middleton, PhD, Nestlé Purina Research, Senior Research Scientist, Pet Care Basic Research at the 2011 National Parent Club Canine Health Conference hosted by the AKC Canine Health Foundation.

Canine Hemangiosarcoma Research

In this special 35 minute edition of Genome Barks we hear from Dr. Jaime Modiano of the University of Minnesota. Dr. Modiano discusses his CHF-funded research of hemangiosarcoma, as well as providing an overview on the progress being made in the field of hemangiosarcoma research.

This podcast was made possible thanks to the generous support of the Kenneth A. Scott Charitable Trust, a KeyBank Trust.

Canine Oncology Clinical Trials

Presentation by Douglas H. Thamm, VMD DACVIM, Colorado State University Animal Cancer Center Associate Professor & Barbara Cox Anthony Chair in Oncology and Director of Clinical Research at the 2011 National Parent Club Canine Health Conference hosted by the AKC Canine Health Foundation.

This presentation answers the questions: What is a clinical trial? Why are clinical trials conducted in dogs with cancer? What are the different types of clinical trials? What are the phases of clinical trials? When are clinical trials appropriate for a pet? How can I find information about available clinical trials for dogs with cancer?

Health Testing in the AKC Breeder of Merit Program

Susan Hamil, AKC Delegate and AKC Canine Health Foundation Director, discusses health testing requirements in the AKC Breeder of Merit Program. This presentation was made at the 2011 National Parent Club Canine Health Conference hosted by the AKC Canine Health Foundation.

Factors Influencing Development of New Veterinary Medicine Oncology Products

Presenation made by Karen Greenwood, BSc, Director, Companion Animal Internal Medicine Unit at Pfizer Animal Health at the 2011 National Parent Club Canine Health Conference hosted by the AKC Canine Health Foundation.

Presenation Abstract:
The presentation will cover the process involved in identifying and registering new oncology treatments for canines and the factors that influence successful registration and launch. This will include observations on the challenge and complexity of development for agents specifically developed for pets versus off-label use of human health products, the MUMS (minor use, minor species) process as it relates to oncology, and the benefits of translational oncology for canine cancer patients.